Involvement of Uric Acid Transporters in Alteration of Serum Uric Acid Level by Angiotensin II Receptor Blockers

[1] Alderman M. H.(1999)Serum uric acid and cardiovascular events in successfully treated hypertensive patients Hypertension 34 144-150

[2] Cohen H.(2000)Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study Hypertension 36 1072-1078

[3] Madhavan S.(2000)Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Losartan Trial Investigators Clin. Ther. 22 1186-1203

[4] Kivlighn S.(2001)Losartan Clin. Ther. 23 1166-1179

[5] Verdecchia P.(1992) valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial Eur. J. Clin. Pharmacol. 42 333-335

[6] Schillaci G.(1993)Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects Hypertension 22 339-347

[7] Reboldi G.(1996)Brunner salt-dependent renal effects of an angiotensin II antagonist in healthy subjects J. Cardiovasc. Pharmacol. 28 259-263

[8] Santeusanio S. C.(1985)Effects of losartan on renal function in patients with essential hypertension Arch. Intern. Med. 145 1492-1503

[9] Porcellati C.(2005)The development of allopurinol Physiology 20 125-133

[10] Manolis A. J.(2002)Molecular physiology of urate transport Nature 417 447-452

[1] Alderman M. H.(1999)Serum uric acid and cardiovascular events in successfully treated hypertensive patients Hypertension 34 144-150

[2] Cohen H.(2000)Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study Hypertension 36 1072-1078

[3] Madhavan S.(2000)Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Losartan Trial Investigators Clin. Ther. 22 1186-1203

[4] Kivlighn S.(2001)Losartan Clin. Ther. 23 1166-1179

[5] Verdecchia P.(1992) valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial Eur. J. Clin. Pharmacol. 42 333-335

[6] Schillaci G.(1993)Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects Hypertension 22 339-347

[7] Reboldi G.(1996)Brunner salt-dependent renal effects of an angiotensin II antagonist in healthy subjects J. Cardiovasc. Pharmacol. 28 259-263

[8] Santeusanio S. C.(1985)Effects of losartan on renal function in patients with essential hypertension Arch. Intern. Med. 145 1492-1503

[9] Porcellati C.(2005)The development of allopurinol Physiology 20 125-133

[10] Manolis A. J.(2002)Molecular physiology of urate transport Nature 417 447-452